HCW Biologics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCWB research report →
Companywww.hcwbiologics.com
HCW Biologics Inc. , a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.
- CEO
- Hing C. Wong
- IPO
- 2021
- Employees
- 36
- HQ
- Miramar, FL, US
Price Chart
Valuation
- Market Cap
- $5.07M
- P/E
- -3.13
- P/S
- 0.77
- P/B
- 0.88
- EV/EBITDA
- -9.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.24%
- Op Margin
- -97.88%
- Net Margin
- -24.73%
- ROE
- -102.39%
- ROIC
- -38.43%
Growth & Income
- Revenue
- $54.23K · -97.89%
- Net Income
- $-7,959,709 · 73.49%
- EPS
- $-10.63 · -1280.52%
- Op Income
- $-11,257,288
- FCF YoY
- 7.57%
Performance & Tape
- 52W High
- $9.20
- 52W Low
- $0.25
- 50D MA
- $0.49
- 200D MA
- $2.14
- Beta
- 1.14
- Avg Volume
- 16.82M
Get TickerSpark's AI analysis on HCWB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 16, 25 | Wong Hing C | buy | 8,054 |
| May 16, 25 | Winer Gary M | buy | 1,342 |
| May 16, 25 | GARRETT SCOTT T | buy | 13,423 |
| May 8, 25 | Winer Gary M | buy | 2,308 |
| May 7, 25 | Winer Gary M | buy | 1,154 |
| May 8, 25 | Wong Hing C | buy | 92,500 |
| May 7, 25 | Wong Hing C | buy | 46,250 |
| May 8, 25 | GARRETT SCOTT T | buy | 5,385 |
| May 7, 25 | GARRETT SCOTT T | buy | 2,692 |
| May 8, 25 | Byam Rebecca | buy | 8,462 |
Our HCWB Coverage
We haven't published any research on HCWB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HCWB Report →